Stockscreener 앱 받기
819.14
3.21%
-27.13
전일 마감가:
$846.27
열려 있는:
$842.8
하루 거래량:
388.97K
Relative Volume:
0.66
시가총액:
$51.51B
수익:
$4.16B
순이익/손실:
$1.29B
주가수익비율:
41.83
EPS:
19.5837
순현금흐름:
$734.26M
1주 성능:
-0.71%
1개월 성능:
-16.81%
6개월 성능:
-1.11%
1년 성능:
-2.17%
1일 변동 폭
$813.05
$843.61
1주일 범위
$798.48
$858.21
52주 변동 폭
$661.85
$1,072.75
알제넥스 NV ADR Stock (ARGX) Company Profile
Compare ARGX vs VRTX, MRNA, REGN, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
알제넥스 NV ADR Stock (ARGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-26 | 업그레이드 | UBS | Neutral → Buy |
| 2026-08-24 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2026-08-04 | 재개 | Guggenheim | Buy |
| 2026-03-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-12-18 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 재개 | Truist | Buy |
| 2025-09-11 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-13 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2025-01-17 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2024-11-12 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Strong Buy |
| 2024-10-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-08-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-07-25 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-07-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 개시 | Scotiabank | Sector Perform |
| 2023-07-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-07-17 | 재개 | Evercore ISI | Outperform |
| 2023-06-15 | 개시 | Societe Generale | Sell |
| 2023-05-31 | 개시 | UBS | Buy |
| 2023-04-25 | 개시 | Citigroup | Buy |
| 2023-03-14 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 개시 | William Blair | Outperform |
| 2022-10-12 | 개시 | Oppenheimer | Perform |
| 2022-07-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 재개 | Stifel | Buy |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-11-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-23 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 개시 | Deutsche Bank | Hold |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-06-18 | 개시 | UBS | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 개시 | Redburn | Neutral |
| 2021-03-05 | 재확인 | H.C. Wainwright | Neutral |
| 2021-02-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 개시 | H.C. Wainwright | Neutral |
| 2020-02-10 | 개시 | BofA/Merrill | Buy |
| 2019-11-05 | 개시 | Credit Suisse | Neutral |
| 2019-10-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 개시 | JP Morgan | Overweight |
| 2019-09-27 | 개시 | Wells Fargo | Market Perform |
| 2019-09-16 | 재개 | Cowen | Outperform |
| 2019-06-28 | 개시 | Robert W. Baird | Outperform |
| 2019-01-18 | 재개 | SunTrust | Buy |
| 2019-01-04 | 개시 | Morgan Stanley | Overweight |
| 2018-12-17 | 개시 | Goldman | Buy |
| 2018-12-14 | 개시 | Wolfe Research | Outperform |
| 2018-06-29 | 개시 | Nomura | Buy |
| 2018-04-09 | 개시 | SunTrust | Buy |
| 2018-01-29 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
알제넥스 NV ADR 주식(ARGX)의 최신 뉴스
Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR - Zacks Investment Research
Best 3 Non-AI Stocks to Buy Now on the Dip Amid the AI Stock Selloff - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 - GlobeNewswire Inc.
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
argenx reports Phase 2 FB102 celiac trial met primary endpoint - Mugglehead Investment Magazine
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - Zacks Investment Research
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? - The Motley Fool
argenx SE (1AE.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx SE (ARGX.BR) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline - GlobeNewswire Inc.
SGIOY Stock Price, Quote & News - Syfe
argenx at wells fargo healthcare conference: broadening beyond vyvgart By Investing.com - Investing.com India
argenx at wells fargo healthcare conference: broadening beyond vyvgart - investing.com
Argenx Se Stock Price Forecast. Should You Buy ARGX? - StockInvest.us
argenx SEADR Key Financial Ratios – Valuation, Profitability & More - Value Research
argenx to Present at Upcoming Investor Conferences - Barchart.com
BNTX Stock Price, Quote & News - Syfe
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportSocial Sentiment - siam.in
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportBlue Chip Entry Points - dars.gov.et
argenx SEADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Resilient Argenx stock holds near record highs after Forte Biosciences acquisition - ad-hoc-news.de
Resilient Argenx stock touches fresh all-time high after Forte Biosciences deal - ad-hoc-news.de
Argenx stock hits all-time high at 1059.86 USD By Investing.com - Investing.com South Africa
argenx Completes Acquisition of Forte Biosciences, Inc. - Barchart.com
Forte Biosciences Director David W. Gryska Sells Entire Stake Amid Merger with argenx BV - Kalkine Media
Argenx Completes Acquisition of Forte Biosciences - marketscreener.com
Why is Argen-X stock climbing today? By Investing.com - Investing.com UK
UBS upgrades argenx stock rating on Vyvgart sales outlook By Investing.com - Investing.com India
Why is Argen-X stock climbing today? - investing.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Argenx keeps climbing, shrugging off Deutsche Bank's reservations - marketscreener.com
Deutsche Bank Downgrades Argenx to Hold, Lifts PT - www.marketscreener.com
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Nigeria
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Australia
Deutsche Bank downgrades argenx stock to Hold on valuation - Investing.com
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Resilient Argenx stock climbs after positive myositis data and fresh analyst targets - Ad-hoc-news.de
RBC Capital raises argenx stock price target on myositis data - Investing.com
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - Ad-hoc-news.de
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
argenx (ARGX) Latest Price Review: Adds 0.52% to Close at $992.99; Key Levels: the Supplied Trading Band Runs From $943.34 to $1,042.64 for the Current SessionMerger Arbitrage - dars.gov.et
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - Morningstar
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - Ad-hoc-news.de
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com Australia
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Benzinga
알제넥스 NV ADR (ARGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.34%
2.25%
자본화:
|
볼륨(24시간):